(1) Division of Surgical Oncology, Department of Surgery, The University of Illinois at Chicago, Chicago, IL, USA;(2) Division of Hematology and Oncology, The University of Chicago, Chicago, IL, USA
Abstract:
Background
The prognosis of peritoneal sarcomatosis is generally poor and conventional treatments for this disease process are mostly ineffective. The use of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) as an aggressive locoregional treatment option remains controversial.